CBiPES

CBiPES

CBiPES
Systematic (IUPAC) name
N-(4'-cyano-[1,1'-biphenyl]-3-yl-N-(3-pyridinylmethyl)ethanesulfonamide
Clinical data
Legal status
?
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider
Chemical data
Formula C21H19N3O2S 
Mol. mass 377.459 g/mol

CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR2 receptors in schizophrenia and related disorders.[1][2][3]

References

  1. ^ Johnson, M. P.; Barda, D.; Britton, T. C.; Emkey, R.; Hornback, W. J.; Jagdmann, G. E.; McKinzie, D. L.; Nisenbaum, E. S.; Tizzano, J. P.; Schoepp, D. D. (2005). "Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology 179 (1): 271–283.  
  2. ^ Fell, M. J.; Katner, J. S.; Johnson, B. G.; Khilevich, A.; Schkeryantz, J. M.; Perry, K. W.; Svensson, K. A. (2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology 58 (3): 632–639.  
  3. ^ Sanger, H.; Hanna, L.; Colvin, E. M.; Grubisha, O.; Ursu, D.; Heinz, B. A.; Findlay, J. D.; Vivier, R. G.; Sher, E.; Lodge, D.; Monn, J. A.; Broad, L. M. (2012). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology 66: 264–273.